New Delhi: Drug firm Cipla on Tuesday said it plans to launch fixed-dose combination anti-malarial drug in India in partnership with non-profit organisation, Drugs for Neglected Diseases Initiative (DNDi).The company said it has collaborated with DNDi to launch fixed-dose combination of Artesunate (AS) and Mefloquine (MQ) to treat malaria caused by microorganism `P falciparum`.
Modi formally accepts Obama`s invitation
`Ganga aarti` drone shoot: Varanasi on terror radar?
Gavaskar wants salary as BCCI interim president
Bokaro rape case condemned across political spectrum